Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Given the established role of 90 kDa ribosomal S6 kinases (Rsk) in oncogenesis, and the promise of new Rsk-blocking cancer treatments, it is perhaps surprising that Rsk2-mediated inhibition of hyperplasia has now been demonstrated to occur in the arthritic synovium. Does this functional duality make Rsk2 a risky target for the treatment of rheumatoid arthritis?

Original publication

DOI

10.1038/nrrheum.2015.1

Type

Journal article

Journal

Nat rev rheumatol

Publication Date

04/2015

Volume

11

Pages

203 - 205

Keywords

Animals, Antirheumatic Agents, Arthritis, Rheumatoid, Biomarkers, Evidence-Based Medicine, Fibroblasts, Gelatinases, Humans, Hyperplasia, Membrane Proteins, Phenotype, Ribosomal Protein S6 Kinases, 90-kDa, Serine Endopeptidases, Synovial Fluid